Celldex Therapeutics Stock Price, News & Analysis (NASDAQ:CLDX)

$2.98 0.04 (1.36 %)
(As of 12/13/2017 04:00 PM ET)
Previous Close$2.98
Today's Range$2.91 - $3.05
52-Week Range$2.20 - $4.07
Volume1.70 million shs
Average Volume1.15 million shs
Market Capitalization$405.24 million
P/E RatioN/A
Dividend YieldN/A
Beta2.71

About Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients. Its Glembatumumab vedotin (also referred to as CDX-011) is meant for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody. Its earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. It includes a multi-faceted tumor-associated macrophage (TAM) program. The Company's pipeline also includes CDX-0158 and CDX-3379, which are humanized monoclonal antibodies.

Receive CLDX News and Ratings via Email

Sign-up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:CLDX
CUSIP15117B10
Phone+1-908-2007500

Debt

Debt-to-Equity RatioN/A
Current Ratio5.91%
Quick Ratio5.91%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$6.79 million
Price / Sales59.68
Cash FlowN/A
Price / CashN/A
Book Value$2.17 per share
Price / Book1.37

Profitability

Trailing EPS($1.01)
Net Income$-128,530,000.00
Net Margins-1,088.58%
Return on Equity-46.94%
Return on Assets-32.11%

Miscellaneous

Employees210
Outstanding Shares135,990,000

Celldex Therapeutics (NASDAQ:CLDX) Frequently Asked Questions

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) released its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.07. The biopharmaceutical company had revenue of $3.90 million for the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The firm's revenue for the quarter was up 77.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.29) EPS. View Celldex Therapeutics' Earnings History.

Where is Celldex Therapeutics' stock going? Where will Celldex Therapeutics' stock price be in 2017?

6 brokerages have issued twelve-month price objectives for Celldex Therapeutics' stock. Their forecasts range from $3.50 to $10.00. On average, they expect Celldex Therapeutics' share price to reach $8.13 in the next year. View Analyst Ratings for Celldex Therapeutics.

What are Wall Street analysts saying about Celldex Therapeutics stock?

Here are some recent quotes from research analysts about Celldex Therapeutics stock:

  • 1. According to Zacks Investment Research, "Celldex’s efforts to build its immuno-oncology pipeline are impressive. Its lead pipeline candidate, glembatumumab vedotin, is in mid-stage development for different types of cancer.  Apart from glembatumumab vedotin, Celldex has several promising candidates in its pipeline, including varlilumab. We are also encouraged by Celldex’s partnership agreements with big players like Bristol-Myers. Meanwhile, the recent Kolltan acquisition adds some interesting candidates to the company’s pipeline. However, with no approved product in its portfolio, Celldex has to depend entirely on product development and licensing agreements, contracts and grants for revenues. We are also concerned about the early- to mid-stage nature of its pipeline. Estimates have remained mostly stable lately ahead of the Q2 results. Celldex has a positive record of earnings surprises in the recent quarters. " (7/17/2017)
  • 2. Cowen Inc analysts commented, "At ASCO updates on varli and glemba were provided." (6/6/2017)
  • 3. Jefferies Group LLC analysts commented, "The PIII METRIC trial evaluating glemba has observed recent patient acceleration due to new EU sites and driving a potential enrollment completion by Sept 2017. Based on this timeline, data could be available in 2Q18, and we remain less optimistic on the success of the trial. In '17, we should receive data from PI portion of varli+nivo." (3/15/2017)

Who are some of Celldex Therapeutics' key competitors?

Who are Celldex Therapeutics' key executives?

Celldex Therapeutics' management team includes the folowing people:

  • Larry Ellberger, Independent Chairman of the Board (Age 69)
  • Anthony S. Marucci, President, Chief Executive Officer, Director (Age 55)
  • Sam Martin, Chief Financial Officer, Senior Vice President (Age 46)
  • Tibor Keler Ph.D., Executive Vice President and Chief Scientific Officer (Age 58)
  • Sarah Cavanaugh, Senior Vice President - Corporate Affairs and Administration (Age 42)
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer (Age 45)
  • Margo Heath-Chiozzi, Senior Vice President - Regulatory Affairs (Age 60)
  • Theresa M. LaVallee Ph.D., , Senior Vice President - Regulatory and Precision Medicine (Age 50)
  • Ronald A. Pepin Ph.D., Senior Vice President and Chief Business Officer (Age 61)
  • Richard Wright Ph.D., Senior Vice President, Chief Commercial Officer` (Age 53)

Who owns Celldex Therapeutics stock?

Celldex Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Meditor Group Ltd (4.92%), Dimensional Fund Advisors LP (0.63%), Bank of New York Mellon Corp (0.48%), Schwab Charles Investment Management Inc. (0.42%), Ameriprise Financial Inc. (0.34%) and Russell Investments Group Ltd. (0.27%). View Institutional Ownership Trends for Celldex Therapeutics.

Who sold Celldex Therapeutics stock? Who is selling Celldex Therapeutics stock?

Celldex Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Canada Pension Plan Investment Board, Oppenheimer & Co. Inc., Schwab Charles Investment Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Celldex Therapeutics.

Who bought Celldex Therapeutics stock? Who is buying Celldex Therapeutics stock?

Celldex Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Meditor Group Ltd, Russell Investments Group Ltd., Dynamic Technology Lab Private Ltd, Ameriprise Financial Inc., OxFORD Asset Management LLP, Cubist Systematic Strategies LLC, Dimensional Fund Advisors LP and Bank of New York Mellon Corp. View Insider Buying and Selling for Celldex Therapeutics.

How do I buy Celldex Therapeutics stock?

Shares of Celldex Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celldex Therapeutics' stock price today?

One share of Celldex Therapeutics stock can currently be purchased for approximately $2.98.

How big of a company is Celldex Therapeutics?

Celldex Therapeutics has a market capitalization of $405.24 million and generates $6.79 million in revenue each year. The biopharmaceutical company earns $-128,530,000.00 in net income (profit) each year or ($1.01) on an earnings per share basis. Celldex Therapeutics employs 210 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 Frontage Rd Ste 220, HAMPTON, NJ 08827-4034, United States. The biopharmaceutical company can be reached via phone at +1-908-2007500 or via email at [email protected]


MarketBeat Community Rating for Celldex Therapeutics (CLDX)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  358 (Vote Outperform)
Underperform Votes:  165 (Vote Underperform)
Total Votes:  523
MarketBeat's community ratings are surveys of what our community members think about Celldex Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celldex Therapeutics (NASDAQ:CLDX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.782.752.752.55
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.36$8.64$8.64$7.56
Price Target Upside: 188.18% upside214.29% upside237.61% upside216.42% upside

Celldex Therapeutics (NASDAQ:CLDX) Consensus Price Target History

Price Target History for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/6/2017WBB SecuritiesReiterated RatingBuy$10.00LowView Rating Details
11/7/2017HC WainwrightReiterated RatingBuyN/AView Rating Details
9/26/2017Cantor FitzgeraldReiterated RatingBuy$9.00LowView Rating Details
6/29/2017AegisReiterated RatingBuyMediumView Rating Details
6/6/2017CowenReiterated RatingBuyHighView Rating Details
5/11/2017Jefferies GroupReiterated RatingHold$4.00 -> $3.50HighView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$7.00N/AView Rating Details
11/8/2016WedbushReiterated RatingNeutral$3.00N/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$16.00N/AView Rating Details
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00N/AView Rating Details
3/7/2016OppenheimerDowngradeOutperform -> Market PerformN/AView Rating Details
3/7/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Celldex Therapeutics (NASDAQ:CLDX) Earnings History and Estimates Chart

Earnings by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ CLDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.27)($0.20)$1.30 million$3.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.28)($0.23)$1.21 million$3.83 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.29)($0.28)$0.57 million$1.53 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.34)($0.30)$1.10 million$1.87 millionViewListenView Earnings Details
11/7/2016Q3 2016($0.33)($0.29)$1.09 million$2.20 millionViewN/AView Earnings Details
8/8/2016Q2($0.34)($0.32)$0.96 million$1.39 millionViewListenView Earnings Details
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details
11/5/2015Q3($0.35)($0.32)$1.02 million$1.03 millionViewN/AView Earnings Details
8/10/2015Q215($0.34)($0.33)$0.51 million$2.18 millionViewListenView Earnings Details
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details
11/4/2014Q3($0.33)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details
8/6/2014Q214($0.31)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details
5/1/2014Q1 2014($0.26)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Celldex Therapeutics (NASDAQ:CLDX) Earnings Estimates

2017 EPS Consensus Estimate: ($1.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.30)($0.26)($0.28)
Q2 20173($0.27)($0.23)($0.26)
Q3 20173($0.28)($0.20)($0.24)
Q4 20173($0.29)($0.20)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celldex Therapeutics (NASDAQ CLDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 52.55%
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)
Insider Trades by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ CLDX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/2/2016Tibor KelerVPBuy3,000$3.32$9,960.00View SEC Filing  
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celldex Therapeutics (NASDAQ CLDX) News Headlines

Source:
DateHeadline
Why Celldex Therapeutics Stock Reversed Course in November - Motley FoolWhy Celldex Therapeutics Stock Reversed Course in November - Motley Fool
www.fool.com - December 10 at 5:25 PM
Why Celldex Therapeutics Stock Reversed Course in NovemberWhy Celldex Therapeutics Stock Reversed Course in November
www.fool.com - December 10 at 9:40 AM
 Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 Million Brokerages Anticipate Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 Million
www.americanbankingnews.com - December 9 at 10:56 AM
ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2017ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 5:08 PM
Zacks: Analysts Expect Celldex Therapeutics, Inc. (CLDX) Will Post Earnings of -$0.20 Per ShareZacks: Analysts Expect Celldex Therapeutics, Inc. (CLDX) Will Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - December 7 at 1:14 PM
Celldex Therapeutics (CLDX) Rating Reiterated by WBB SecuritiesCelldex Therapeutics (CLDX) Rating Reiterated by WBB Securities
www.americanbankingnews.com - December 6 at 11:58 AM
Celldex Begins Phase I Trial on Cancer Candidate CDX-1140 ... - NasdaqCelldex Begins Phase I Trial on Cancer Candidate CDX-1140 ... - Nasdaq
www.nasdaq.com - December 2 at 9:44 AM
Celldex (CLDX) Commences Phase 1 Study of New Product Candidate CDX-1140 in Solid TumorsCelldex (CLDX) Commences Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
www.streetinsider.com - December 1 at 4:56 PM
Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid TumorsCelldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors
finance.yahoo.com - November 30 at 10:04 AM
Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.Better Buy: Ziopharm Oncology Inc. vs. Celldex Therapeutics, Inc.
www.fool.com - November 30 at 9:31 AM
Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
finance.yahoo.com - November 29 at 9:43 AM
Celldex Therapeutics, Inc. (CLDX) Given Average Rating of "Hold" by AnalystsCelldex Therapeutics, Inc. (CLDX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 27 at 4:52 PM
Breakfast Technical Briefing on Biotech Stocks -- Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, and ... - PR Newswire (press release)Breakfast Technical Briefing on Biotech Stocks -- Calithera Biosciences, Celldex Therapeutics, Clovis Oncology, and ... - PR Newswire (press release)
www.prnewswire.com - November 22 at 5:58 PM
Celldex (CLDX) Initiates Phase II Study on Cancer Candidate - NasdaqCelldex (CLDX) Initiates Phase II Study on Cancer Candidate - Nasdaq
www.nasdaq.com - November 22 at 3:28 AM
Zacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 MillionZacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Post Quarterly Sales of $1.91 Million
www.americanbankingnews.com - November 21 at 6:26 AM
ETFs with exposure to Celldex Therapeutics, Inc. : November 20, 2017ETFs with exposure to Celldex Therapeutics, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 6:21 PM
Celldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.20 Per ShareCelldex Therapeutics, Inc. (CLDX) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - November 19 at 5:08 PM
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous ... - GlobeNewswire (press release)Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous ... - GlobeNewswire (press release)
globenewswire.com - November 18 at 8:38 AM
Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell CarcinomaCelldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma
finance.yahoo.com - November 18 at 8:38 AM
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up - NasdaqCelldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up - Nasdaq
www.nasdaq.com - November 10 at 9:53 AM
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : November 9, 2017
finance.yahoo.com - November 9 at 8:11 PM
Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 9 at 8:11 PM
Leerink Swann Analysts Raise Earnings Estimates for Celldex Therapeutics, Inc. (CLDX)Leerink Swann Analysts Raise Earnings Estimates for Celldex Therapeutics, Inc. (CLDX)
www.americanbankingnews.com - November 9 at 8:30 AM
Celldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares UpCelldex (CLDX) Q3 Loss Narrows, Revenues Beat, Shares Up
finance.yahoo.com - November 8 at 9:14 PM
ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017ETFs with exposure to Celldex Therapeutics, Inc. : November 8, 2017
finance.yahoo.com - November 8 at 9:14 PM
Celldex reports 3Q lossCelldex reports 3Q loss
finance.yahoo.com - November 7 at 8:16 PM
Celldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a NumberCelldex Therapeutics, Inc.'s Most Important Takeaway From Q3 Isn't a Number
finance.yahoo.com - November 7 at 8:16 PM
How Much Did Celldex Therapeutics Inc’s (CLDX) CEO Pocket Last Year?How Much Did Celldex Therapeutics Inc’s (CLDX) CEO Pocket Last Year?
finance.yahoo.com - November 7 at 8:16 PM
Celldex Therapeutics, Inc. (CLDX) Announces  Earnings ResultsCelldex Therapeutics, Inc. (CLDX) Announces Earnings Results
www.americanbankingnews.com - November 7 at 5:27 PM
Why Celldex Therapeutics Jumped Higher TodayWhy Celldex Therapeutics Jumped Higher Today
www.fool.com - November 7 at 2:41 PM
Why Celldex Therapeutics Stock Crumbled in OctoberWhy Celldex Therapeutics Stock Crumbled in October
www.fool.com - November 7 at 11:12 AM
Celldex Reports Third Quarter 2017 ResultsCelldex Reports Third Quarter 2017 Results
feeds.benzinga.com - November 7 at 8:26 AM
Is Celldex Therapeutics Inc (CLDX) Undervalued?Is Celldex Therapeutics Inc (CLDX) Undervalued?
finance.yahoo.com - November 6 at 6:30 PM
Celldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by AnalystsCelldex Therapeutics, Inc. (CLDX) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 2 at 5:48 PM
Celldex (CLDX) to Report Q3 Earnings: Whats in the Cards?Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
www.nasdaq.com - November 1 at 6:02 PM
Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?
finance.yahoo.com - November 1 at 6:02 PM
Zacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Announce Quarterly Sales of $1.17 MillionZacks: Brokerages Expect Celldex Therapeutics, Inc. (CLDX) Will Announce Quarterly Sales of $1.17 Million
www.americanbankingnews.com - November 1 at 2:46 PM
Celldex Therapeutics, Inc. (CLDX) to Release Earnings on MondayCelldex Therapeutics, Inc. (CLDX) to Release Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : October 26, 2017Celldex Therapeutics, Inc. – Value Analysis (NASDAQ:CLDX) : October 26, 2017
finance.yahoo.com - October 26 at 5:32 PM
Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 25, 2017Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : October 25, 2017
finance.yahoo.com - October 25 at 6:46 PM
Interesting CLDX Call Options For December 15thInteresting CLDX Call Options For December 15th
www.thestreet.com - October 24 at 7:37 PM
Celldex Therapeutics, Inc. (CLDX) Short Interest Down 42.3% in SeptemberCelldex Therapeutics, Inc. (CLDX) Short Interest Down 42.3% in September
www.americanbankingnews.com - October 13 at 1:32 AM
Short Interest Declines 42.3% For CLDXShort Interest Declines 42.3% For CLDX
www.thestreet.com - October 11 at 6:48 PM
Zacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per ShareZacks: Analysts Anticipate Celldex Therapeutics, Inc. (CLDX) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - October 11 at 2:08 AM
Celldex Therapeutics, Inc. (CLDX) Receives Consensus Recommendation of "Hold" from AnalystsCelldex Therapeutics, Inc. (CLDX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 8 at 2:44 PM
Whats Behind Celldex Therapeutics, Inc.s 16% Rally in September? - Motley FoolWhat's Behind Celldex Therapeutics, Inc.'s 16% Rally in September? - Motley Fool
www.fool.com - October 6 at 5:29 PM
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
finance.yahoo.com - October 6 at 5:29 PM
Whats Behind Celldex Therapeutics, Inc.s 16% Rally in September?What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
www.fool.com - October 6 at 4:45 PM
Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory AffairsCelldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs
finance.yahoo.com - October 3 at 5:07 PM
ETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017ETFs with exposure to Celldex Therapeutics, Inc. : September 26, 2017
finance.yahoo.com - October 2 at 5:25 PM

SEC Filings

Celldex Therapeutics (NASDAQ:CLDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celldex Therapeutics (NASDAQ:CLDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celldex Therapeutics (NASDAQ CLDX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.